{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05733013",
            "orgStudyIdInfo": {
                "id": "22-320"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer",
            "officialTitle": "Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-to-collect-information-about-the-use-of-redifferentiating-medications-as-a-standard-treatment-for-thyroid-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-02-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-02-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-02-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-08",
            "studyFirstSubmitQcDate": "2023-02-08",
            "studyFirstPostDateStruct": {
                "date": "2023-02-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study."
        },
        "conditionsModule": {
            "conditions": [
                "Thyroid Cancer",
                "Thyroid",
                "Refractory Thyroid Cancer"
            ],
            "keywords": [
                "RAI refractory thyroid cancer",
                "thyroid cancer",
                "thyroid",
                "Refractory Thyroid Cancer",
                "Radio-iodine refractory thyroid cancer",
                "22-320",
                "Memorial Sloan Kettering Cancer Center"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": true,
            "targetDuration": "100 Years",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Participants with refractory thyroid cancer patients",
                    "interventionNames": [
                        "Other: Surveillance Visit"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Surveillance Visit",
                    "description": "Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.",
                    "armGroupLabels": [
                        "Participants with refractory thyroid cancer patients"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse events will be collected in every visit",
                    "description": "The primary objective of this protocol is to prospectively collect data on patients with radio-iodine refractory thyroid cancer or patients unlikely to respond to radioactive iodine prior, during and after initiation of redifferentiating agents used as part of routine clinical care with or without radioactive iodine treatment.",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients \u2265 18 years old at time of consent\n\nInclusion Criteria:\n\n* Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.\n* Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care.\n* Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration.\n* Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.\n\nExclusion Criteria:\n\n* RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "All patients eligible to receive a redifferentiating agent in the adjuvant setting or in the treatment of structural metastatic disease not enrolled in a clinical trial will be approached for recruitment. All eligible patients will enroll in the study and will be followed indefinitely after enrollment.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Laura Boucai, MD",
                    "role": "CONTACT",
                    "phone": "646-608-3906",
                    "email": "boucail@mskcc.org"
                },
                {
                    "name": "Alan Ho, MD, PhD",
                    "role": "CONTACT",
                    "phone": "646-608-3774",
                    "email": "hoa@mskcc.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Laura Boucai, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Laura Boucai, PhD",
                            "role": "CONTACT",
                            "phone": "646-608-3906"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013964",
                    "term": "Thyroid Neoplasms"
                },
                {
                    "id": "D000013959",
                    "term": "Thyroid Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M16718",
                    "name": "Thyroid Diseases",
                    "asFound": "Thyroid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16723",
                    "name": "Thyroid Neoplasms",
                    "asFound": "Thyroid Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10488",
                    "name": "Iodine",
                    "relevance": "LOW"
                },
                {
                    "id": "M229695",
                    "name": "Cadexomer iodine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}